Organon & Co. (OGN): insider & executive buying
Organon & Co. · Health Care · ref. ETF XLV · price $13.76
In short — 1 insider bought Organon & Co. over ~6 months (1 buy, total $353k, latest May 6, 26). Public Form 4 data, informative (not a performance signal).
Are Organon & Co.'s executives buying their own shares? Here are the disclosed insider buys over the last 6 months — a transparency data point, not an outperformance signal.
📈 1-year price
$13.76+49.9% over range
Aug 28, 25low $5.7 · high $13.77Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
0% recommend buying · 2 analysts
Latest insider buys on Organon & Co.
| Date | Insider | Role | Shares | Amount |
|---|---|---|---|---|
| May 6, 26 | Holzbaur Lynette | SVP, Corporate Controller | 26,448 | $353k |
⚠️ Open-market buys reported to the SEC (Form 4). Transparency data, not advice nor an outperformance signal (our backtests show no reliable edge).
Frequently asked questions
Have Organon & Co.'s executives bought shares recently?
1 Organon & Co. insider(s) bought $353k over ~6 months (latest May 6, 26). A buy shows confidence, but our backtests show no performance edge.
Is insider buying a good signal for OGN?
It's useful transparency data, but NOT a performance guarantee: our historical tests show no reliable edge from following insider buys. Cross-check with fundamentals and analyst views.
Where does this data come from?
From Form 4 filings with the SEC (mandatory for officers and 10%+ holders), aggregated and refreshed regularly.
💬 A question about Organon & Co.? The JPI assistant answers using our backtest data.
Keep exploring Organon & Co.